July 01, 2010
The FDA has approved Purdue's Butrans (buprenorphine) Transdermal System for the management of moderate to severe chronic pain in patients requiring a continuous, around-the-clock opioid analgesic for an extended period of time.
June 04, 2010
The CDC announced the 2009 National Youth Risk Behavior Survey (YRBS) found that 1 in 5 high school students have ever taken a prescription drug such as OxyContin (oxycodone, from Purdue), Percocet (oxycodone/acetaminophen, from Endo), Vicodin (hydrocodone/acetaminophen, from Abbott), Adderall (mixed salts of a single-entity amphetamine product, from Shire), Ritalin (methylphenidate, from Novartis), or Xanax (alprazolam, from Pfizer), without a prescription.
May 25, 2010
AcelRx Pharmaceuticals announced positive results from a Phase 2 clinical study evaluating the safety and efficacy of its ARX-02 sufentanil NanoTab Breakthrough Pain Management System in the treatment of cancer breakthrough pain in opioid-tolerant patients.
May 11, 2010
The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.
April 26, 2010
Exalgo (hydromorphone HCl extended-release tablets) has been launched by Covidien for the management of moderate to severe pain in opioid-tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time.